These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11987434)

  • 1. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables.
    Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
    Int J Technol Assess Health Care; 2002; 18(1):112-9. PubMed ID: 11987434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic league tables: communicating cost-effectiveness results to decision-makers.
    Hutubessy RC; Baltussen RM; Evans DB; Barendregt JJ; Murray CJ
    Health Econ; 2001 Jul; 10(5):473-7. PubMed ID: 11466807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stochastic league tables: an application to diabetes interventions in the Netherlands.
    Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
    Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues.
    Coyle D
    Health Econ; 2003 Feb; 12(2):159-62; discussion 163-4. PubMed ID: 12563663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Handling uncertainty of the economic evaluation result: sensitivity analysis.
    Limwattananon S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S59-65. PubMed ID: 19253488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regarding probabilistic analysis and computationally expensive models: necessary and required?
    Caro JJ; Getsios D; Möller J
    Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
    [No Abstract]   [Full Text] [Related]  

  • 8. Generalised cost-effectiveness analysis: an aid to decision making in health.
    Hutubessy RC; Baltussen RM; Torres-Edejer TT; Evans DB
    Appl Health Econ Health Policy; 2002; 1(2):89-95. PubMed ID: 14619255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inquiry into the principles of needs-based allocation of health care.
    Hope T; Osterdal LP; Hasman A
    Bioethics; 2010 Nov; 24(9):470-80. PubMed ID: 19508305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
    Claxton K; Sculpher M; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J; O'Hagan T
    Health Econ; 2005 Apr; 14(4):339-47. PubMed ID: 15736142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.
    Al MJ; Feenstra TL; Hout BA
    Health Econ; 2005 Jul; 14(7):655-67. PubMed ID: 15678518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis and formulary decision making in England: findings from research.
    Williams IP; Bryan S
    Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.
    O'Hagan A; Stevenson M; Madan J
    Health Econ; 2007 Oct; 16(10):1009-23. PubMed ID: 17173339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment in the cost-disutility plane.
    Eckermann S; Briggs A; Willan AR
    Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.